Imagine what Pfizer could do with Vascepa for CVD.
Could, assuming this is the reason for the PFE deal with HLS, Pfizer is not imagining what they could do with V, they actually want to find out first. As someone here mentioned recently, there may be a lot of things to overcome to get V to the sales level we think (i.e. supplements, docs preconditioned to recommend supplements instead of V, docs acceptance of V, etc.) and PFE wants to be sure.